New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
09:09 EDTSTMP, VCLK, WTW, NSPH, CTL, CAB, AAMRQ, STZ, ANGI, LCC, BRK.A, ART, BUD, HNZOn The Fly: Pre-market Movers
UP AFTER DEALS: Constellation Brands (STZ), up 29.4% after agreeing to a revised agreement with Anheuser-Busch InBev (BUD) under which Constellation will buy Modelo's Piedras Negras brewery and be granted perpetual rights for Corona and other Modelo brands in the U.S. at a cost of $2.9B. AB InBev shares also up 5.3%... Heinz (HNZ), up 19.8% after agreeing to be acquired by Berkshire Hathaway (BRK.A) and 3G Capital for $72.50 per share in cash... US Airways (LCC), up 1.9% after approving merger with AMR Corp. (AAMRQ) with combined equity value of $11B... Artio Global (ART), up 33.2%, to be acquired by Aberdeen Asset Management for $2.75 per share... UP AFTER EARNINGS: Angie's List (ANGI), up 28.5%... ValueClick (VCLK), up 7.2%... DOWN AFTER EARNINGS: Nanosphere (NSPH), down 20.5%... Stamps.com (STMP), down 19.3%... TripAdvisor (TRIP), down 10%... Whole Foods (WFM), down 6.7%... Tata Motors (TTM), down 6.3%... ALSO LOWER: CenturyLink (CTL), down 17.3% after quarterly report, dividend cut, multiple analyst downgrades... Weight Watchers (WTW), down 17.4% after results, resignation of Chief Technology Officer.
News For A;STZ;BUD;LCC;AAMRQ;ART;ANGI;VCLK;CAB;NSPH;STMP;CTL;WTW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
16:06 EDTNSPHNanosphere announces 18 studies using Verigene tests recently presented
Subscribe for More Information
10:06 EDTSTMPHigh option volume stocks
Subscribe for More Information
May 26, 2015
17:41 EDTNSPHPerella Weinberg Partners reports 9.3% passive stake in Nanosphere
Subscribe for More Information
16:14 EDTNSPHSWK Holdings reports 6.4% passive stake in Nanosphere
Subscribe for More Information
May 24, 2015
16:20 EDTAAgilent to host analyst meeting
Subscribe for More Information
May 21, 2015
10:12 EDTWTWOptions with decreasing implied volatility
Subscribe for More Information
May 20, 2015
16:29 EDTAAgilent appoints Rodney Gonsalves as principal accounting officer
Subscribe for More Information
10:29 EDTWTWOptions with decreasing implied volatility
Options with decreasing implied volatility: ZIOP KING ARIA CTRP WTW VHC XON KERX VIPS JCP
May 19, 2015
11:59 EDTWTWOptions with decreasing implied volatilit
Subscribe for More Information
09:06 EDTSTMPChoxi announces new partnership with Stamps.com subsidiary
Subscribe for More Information
May 18, 2015
19:12 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
May 15, 2015
12:13 EDTBUDThird Point gives quarterly update on stakes
NEW STAKES: Yum! Brands (YUM), NXP Semiconductors (NXPI), FedEx (FDX), McKesson (MCK), and J M Smucker (SJM). INCREASED STAKES: Actavis (ACT), Roper Technologies (ROP), Delta Air Lines (DAL), and FleetCor Technologies (FLT). DECREASED STAKES: Ally Financial (ALLY), Amgen (AMGN), Phillips 66 (PSX), eBay (EBAY), and Anheuser Busch Inbev SA (BUD). LIQUIDATED STAKES: Alibaba Group (BABA), Citigroup (C), EMC Corporation (EMC), Anglo American (AAL), and Williams Companies (WMB).
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use